We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Anticancer Therapies – Products

High-Quality Cytokines for T Cell Culture content piece image
Product
Advertisement

High-Quality Cytokines for T Cell Culture

T cell-mediated therapies, such as CAR-T or tumor-infiltrating lymphocytes therapies, hold promise to transform cancer treatment to be more personalized and effective. Cytokines have a fundamental role in T cell survival, expansion, and differentiation.
ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement content piece image
Product News

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD.
Pre-Clinical Screening Technology Increases Cancer Test Numbers content piece image
Product News

Pre-Clinical Screening Technology Increases Cancer Test Numbers

A screening tool developed in research led at the University of Strathclyde, UK could increase the number of tests on a solid tumor sample by up to 50 times.
Vaccizone Selects Exothera for Process Development and GMP Manufacturing of its SARS-CoV-2 Vaccine content piece image
Product News

Vaccizone Selects Exothera for Process Development and GMP Manufacturing of its SARS-CoV-2 Vaccine

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS-CoV-2 vaccine for European clinical trials.

Type I IFNs: First-Line of Defense Against Viral Infections and Neoplastic Transformation content piece image
Product
Advertisement

Type I IFNs: First-Line of Defense Against Viral Infections and Neoplastic Transformation

Sino Biological has developed an array of high-quality Proteins, Antibodies, Genes, Lysate, and qPCR Primer Pairs to support the study of IFN-Is.
Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin content piece image
Product News

Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.
Expansion of Specific Lymphocyte Populations content piece image
App Note / Case Study

Expansion of Specific Lymphocyte Populations

Expansion of Specific Lymphocyte Populations With 4Cell® Nutri-T Xeno-Free, Serum-Free Medium

The success of CAR T-cell therapy requires efficient expansion of specific subpopulations of patient-derived immune cells.
PD-1/PD-L1 Combination Therapy in Cancer Treatment content piece image
Whitepaper

PD-1/PD-L1 Combination Therapy in Cancer Treatment

Cancer immunotherapy, especially the use of immune checkpoint inhibitors, has been successful in improving the treatment landscape of malignancies.
SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics content piece image
Product News

SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics

SomaLogic has announced it has signed a licensing agreement with OncoHost.
Therapeutic Targets in CAR NK-Cell Therapy content piece image
Product
Advertisement

Therapeutic Targets in CAR NK-Cell Therapy

Natural killer (NK) cells are immune cells capable of killing target cells and can be genetically modified to express chimeric antigen receptors (CARs). CAR NK-cell therapy is an innovative type of cancer immunotherapy for solid tumors and hematological malignancies.
Advertisement